Pishvaian MJ, Lee MS, Ryoo B, et al. Updated safety and clinical activity results from a Phase Ib study of atezolizumab + bevacizumab in hepatocellular carcinoma (HCC). ESMO 2018, abstract LBA26.
I-SPY2: voordeel van toevoegen pembrolizumab aan neoadjuvante chemotherapie
mrt 2020 | Borstkanker